about
The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling studyAnalytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectivenessHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactThe Incidence Patterns Model to Estimate the Distribution of New HIV Infections in Sub-Saharan Africa: Development and Validation of a Mathematical ModelRequirements for global elimination of hepatitis B: a modelling study.Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling study.Incorporating incidence information within the UNAIDS Estimation and Projection Package framework: a study based on simulated incidence assay data.Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era.Providing a conceptual framework for HIV prevention cascades and assessing feasibility of empirical measurement with data from east Zimbabwe: a case study.The potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya.Gender-Specific Combination HIV Prevention for Youth in High-Burden Settings: The MP3 Youth Observational Pilot Study Protocol.How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?The price of sex: condom use and the determinants of the price of sex among female sex workers in eastern Zimbabwe.Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidenceUnderstanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community.Development and future directions for the Joint United Nations Programme on HIV/AIDS estimates.Estimating HIV incidence from case-report data: method and an application in ColombiaEmbracing different approaches to estimating HIV incidence, prevalence and mortality.Recent HIV prevalence trends among pregnant women and all women in sub-Saharan Africa: implications for HIV estimates.Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The NetherlandsEarly HIV infection in the United States: a virus's eye viewThe distribution of sex acts and condom use within partnerships in a rural sub-Saharan African population.Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention.Sustainable HIV treatment in Africa through viral-load-informed differentiated care.Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study.PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa.Modeling the impact of interventions along the HIV continuum of care in Newark, New Jersey.Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa.The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models.Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.HIV and risk environment for injecting drug users: the past, present, and future.Estimating the range of potential epidemiological impact of pre-exposure prophylaxis: run-away success or run-away failure?Using modeling to inform international guidelines for antiretroviral treatment.A side door into care cascade for HIV-infected patients?Putting the burden of HIV in context.Consequences of a changing US strategy in the global HIV investment landscape.Research on hormonal contraception and HIV - Authors' reply.Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries.
P50
Q28484308-6841489A-C5EB-4762-B307-764F126E3F09Q28535414-05DB23E5-EEC4-4AC6-82B4-96639A9D593DQ28552455-53B1B282-FAD3-4AAB-ADD4-3243C7935009Q28554022-7123CEBB-51D5-409C-9AF5-16DDFC89C84FQ30061950-806BFAAC-AF6C-475C-8AE9-676ACCAD9F5EQ30392253-D7334488-8DB5-4034-B8CC-214994D2A580Q30870458-0F312A7E-494B-4B7E-B4DC-FD80E997E34FQ30994543-D4E68438-3907-45F8-8157-E7BBD929033CQ31111694-45D0D520-FD39-4BB3-AB3B-D0B219D8EED0Q33558726-6AB35AEA-FFD0-4843-B5B4-751A259E387AQ33697680-D2CE78ED-E0FE-410D-A5B3-0D49243CFBD3Q33873878-EC55CF12-DB8B-47CE-A915-FFB97BE31226Q34509554-150D490B-D77F-4413-B458-A6BA9CC5348FQ34526461-0512E6AE-EBE4-4176-A429-F8AA8E679CA3Q34571215-73594F20-5D7F-4D14-92FC-3129BD4F8A74Q34585098-598DD227-C945-45E9-87A2-EBF7D49EE257Q34585105-B913E9EA-22C7-4385-901A-1CF2885C6CBDQ34585124-3CCA02F7-3F9A-4C0A-A669-AC7AA81DFDB4Q34585148-B38C1A30-BE74-4CCE-85C8-8B1F717C1025Q35010207-D09C4F4C-6915-4245-A7CB-4FF687A5DB41Q35067151-FBC8440F-A02E-407D-B3FE-3FBA62F8EE2DQ35099556-602E7E38-A765-4394-B348-700FB047B6ABQ35504333-73687EA7-5FA2-40EA-9D3F-800C0D433E40Q35875733-50E0DA86-0095-47B6-B4DB-668AB2B37725Q37064741-3C23E741-0B81-420F-973F-DBF317C20893Q37072195-F65962C5-C5BE-4701-AF56-DF971F97F943Q37352500-AE545959-3326-4333-8746-D33E3E3936BFQ37411691-68B6C77A-1E40-4771-9201-896E17483D76Q38860584-1657F401-1EB0-4E66-BE60-097BAEDFA5F7Q39218820-06719AE6-1792-429C-81C0-5BD497F16D7DQ39368441-ACE4EABB-E588-4372-9370-259F05F398A5Q39574817-1E4C61A8-9443-48F9-94E4-8191CC33AA4FQ39854574-5C8113A8-949E-4F27-8939-8324F7048EDDQ41350203-73F18592-7E10-449D-A4FD-3C28C3AAAC91Q42230959-EC9710AE-7934-4513-AEA2-299504D7E716Q42258378-01D7838E-7175-4AA9-89D9-B49DDEF4C167Q44867433-F3A42456-7EB2-4890-A56B-A731605B4B5BQ46524995-F97F1BAB-54AD-411E-94C0-C1096EED6D98Q46765269-BA2E6C82-49B6-40F2-AD2C-0FAA686D3234Q47103647-B94AC2D0-74C6-41F3-A37F-84F4334C6AFD
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Timothy B Hallett
@en
Timothy B Hallett
@nl
type
label
Timothy B Hallett
@en
Timothy B Hallett
@nl
prefLabel
Timothy B Hallett
@en
Timothy B Hallett
@nl
P31
P496
0000-0002-9681-0424